MDK and neoplasm: Overall, the immune microenvironment, angiogenesis, and stromal cell-tumor cell interactions collectively contribute to the aggressive nature and therapy resistance of HB, highlighting potential therapeutic targets such as midkine inhibition and TAM reprogramming [88,90].